BACKGROUND AND OBJECTIVES: Patients who have systemic lupus erythematosus (SLE) and manifest antiphospholipid antibodies (APA) are at increased risk for thrombosis; however, it is difficult to predict who will clot. This study tested the hypothesis that peak D-dimer level measured routinely during follow-up identifies whether a hypercoagulable state is developing and, therefore, the patient is at increased risk for thrombosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred consecutive patients who had SLE with recurrent activity (71% renal SLE) and were evaluated for or enrolled in the Ohio SLE Study were studied. D-dimer testing was done annually and usually at SLE flare or other serious illness. When D-dimer was elevated, evaluation for thrombosis (large vessel, small vessel, or Libman-Sacks) was undertaken. Mean follow-up was 37.5 +/- 15 SD months. RESULTS: Of those with peak D-dimer <0.5 microg/ml (n = 46), 0% thrombosed, 33% had APA. Of those with peak D-dimer 0.5 to 2.0 microg/ml (n = 19), 6% thrombosed, 44% had APA. Of those with peak D-dimer >2.0 microg/ml (n = 36), 42% thrombosed, 76% had APA. The most common causes of elevated D-dimer in the absence of demonstrable thrombosis were SLE flare and systemic infection. D-dimer levels were usually elevated for several months before thrombosis. CONCLUSIONS: Patients with SLE and normal D-dimer levels are at low risk for thrombosis, irrespective of APA status. Those with persistent unexplained elevated D-dimer levels, particularly when >2.0 microg/ml, are at high risk for thrombosis.
BACKGROUND AND OBJECTIVES:Patients who have systemic lupus erythematosus (SLE) and manifest antiphospholipid antibodies (APA) are at increased risk for thrombosis; however, it is difficult to predict who will clot. This study tested the hypothesis that peak D-dimer level measured routinely during follow-up identifies whether a hypercoagulable state is developing and, therefore, the patient is at increased risk for thrombosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred consecutive patients who had SLE with recurrent activity (71% renal SLE) and were evaluated for or enrolled in the Ohio SLE Study were studied. D-dimer testing was done annually and usually at SLE flare or other serious illness. When D-dimer was elevated, evaluation for thrombosis (large vessel, small vessel, or Libman-Sacks) was undertaken. Mean follow-up was 37.5 +/- 15 SD months. RESULTS: Of those with peak D-dimer <0.5 microg/ml (n = 46), 0% thrombosed, 33% had APA. Of those with peak D-dimer 0.5 to 2.0 microg/ml (n = 19), 6% thrombosed, 44% had APA. Of those with peak D-dimer >2.0 microg/ml (n = 36), 42% thrombosed, 76% had APA. The most common causes of elevated D-dimer in the absence of demonstrable thrombosis were SLE flare and systemic infection. D-dimer levels were usually elevated for several months before thrombosis. CONCLUSIONS:Patients with SLE and normal D-dimer levels are at low risk for thrombosis, irrespective of APA status. Those with persistent unexplained elevated D-dimer levels, particularly when >2.0 microg/ml, are at high risk for thrombosis.
Authors: M Di Nisio; A Squizzato; A W S Rutjes; H R Büller; A H Zwinderman; P M M Bossuyt Journal: J Thromb Haemost Date: 2006-11-28 Impact factor: 5.824
Authors: D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert Journal: Clin Exp Immunol Date: 2006-02 Impact factor: 4.330
Authors: S R Levine; L Salowich-Palm; K L Sawaya; M Perry; H J Spencer; H J Winkler; Z Alam; J L Carey Journal: Stroke Date: 1997-09 Impact factor: 7.914
Authors: Brad H Rovin; Huijuan Song; Lee A Hebert; Tibor Nadasdy; Gyongyi Nadasdy; Daniel J Birmingham; Chack Yung Yu; Haikady N Nagaraja Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Daniel J Birmingham; H N Nagaraja; Brad H Rovin; Lacramioara Spetie; Yanxing Zhao; Xiaobai Li; Kevin V Hackshaw; C Yung Yu; William B Malarkey; Lee A Hebert Journal: Arthritis Rheum Date: 2006-10
Authors: G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui Journal: Am J Med Date: 1996-05 Impact factor: 4.965
Authors: Himabindu Vidula; Lu Tian; Kiang Liu; Michael H Criqui; Luigi Ferrucci; William H Pearce; Philip Greenland; David Green; Jin Tan; Daniel B Garside; Jack Guralnik; Paul M Ridker; Nader Rifai; Mary M McDermott Journal: Ann Intern Med Date: 2008-01-15 Impact factor: 25.391
Authors: David Sin; Gordon McLennan; Fabian Rengier; Ihab Haddadin; Gustavo A Heresi; John R Bartholomew; Matthias A Fink; Dustin Thompson; Sasan Partovi Journal: Int J Cardiovasc Imaging Date: 2020-08-30 Impact factor: 2.357